FIG. 1

Constitutively Active Receptors

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP I					
MSHR_mouse	melanocyte-stimulating hormone MSH	TMII	92 VSIVLETTIIL K	adenylyl cyclase activity/ HEK293, *stably transfected*	(Robbins, Nadeau et al. 1993)
CLASS A GROUP II					
5H1B_human	5-hydroxytryptamine$_{1B}$	C-terminus of IC3	313 RERKATKTLGI K,R,Q	binding of [^{35}S]GTP[S] / CHO-KI	(Pauwels, Gouble et al. 1999)
5H2A_human	5-hydroxytryptamine$_{2A}$	C-terminus of IC3	322 NEQKACKVLGI K	IP production / COS-7	(Egan, Herrick-Davis et al. 1998)
2H2C_rat	5-hydroxytryptamine$_{2C}$	C-terminus of IC3	312 NEDDASKVLGI L	PI hydrolysis / COS-7	(Herrick-Davis, Egan et al. 1997)

FIG. 1 (2 of 15)

CLASS A GROUP II					
A1AB_human	α_{1B}-adrenergic alpha 1B-AR	TMDI junction between TMDIII and IC2	63 FAIVGNILVIL A 142 CAISIDRYIGV A	IP / COS-7	(Scheer, Fanelli et al. 1997)
A1AB_human	α_{1B}-adrenergic alpha 1B-AR	junction between TMDIII and IC2	143 CAISIDRYIGV K	IP / COS-7	(Scheer, Costa et al. 2000)
A1AB_human	α_{1B}-adrenergic	TMIII carboxyl end of IC3 TMV	128 AVDVLCCTASI F 293 REKKAAKTLGI E 204 EEPFYALFSSLG V	IP / COS-1 IP arachidonic acid release IP / COS-1	(Perez, Hwa et al. 1996) (Hwa, Gaivin et al. 1997)
A1AB_human	α_{1B}-adrenergic	C-terminal IC3	293 SREKKAAKT X=19 different substitutions	PI / COS-7	(Kjelsberg, Cotecchia et al. 1992)
A1AB_human	α_{1B}-adrenergic	C-terminus IC3	288 293 KFSREKKAAKTLGI K H L	PI hydrolysis / rat fibroblast	(Allen, Lefkowitz et al. 1991)
A2AA_human	α_2C10-adrenergic alpha-2AAR	C-terminal IC3 loop	373 (348?) EKRFTFVLAV X=F, A, C, E, K	adenylyl cyclase inhibition / HEK293	(Ren, Kurose et al. 1993)
ACM1_human	muscarinic Hm1 muscarinic acetylcholine M1	C-terminal IC3 loop junction	360 SLVKEKKAARTLS A	PI / HEK(U293)	(Högger, Shockley et al. 1995)
ACM2-human	muscarinic acetylcholine M2	junction of IC3 and TMVI	390 KKVTRTIL↑A 1-4 A inserted	IP production, inhibition of cAMP production / COS-7	(Liu, Blin et al. 1996)

FIG. 1 (3 of 15)

CLASS A GROUP II					
ACM3_rat	m3 muscarinic (rat) muscarinic acetylcholine M3	TMVI	507 TWTPYNIMVLVNT S	IP / COS-7	(Blüml, Mutschler et al. 1994)
ACM5_human	m5 muscarinic muscarinic acetylcholine M5	N-terminus to TMII TMVI	chimera composed of m2 1-69 m5 77-445 m2 391-466	β-gal / NIH 3T3	(Burstein, Spalding et al. 1996)
ACM5_human	m5 muscarinic muscarinic acetylcholine M5	TMVI	451 459 465 AILLA FIITW TPYNI MVLVST M L H C V S F T	β-gal; radioligand binding / NIH-3T3	(Spalding, Burstein et al. 1998)
ACM5_human	m5 muscarinic muscarinic acetylcholine M5	junction of TMVI and EC3	465 YNIMVLVSTFCDKCV X=V,F,R,K,+more	β-gal; radioligand binding / NIH-3T3	(Spalding, Burstein et al. 1997)
B1AR_human	β_1-adrenergic	C-terminus	389 RKAFQGLLCCA R	adenylyl cyclase; agonist binding / CHW	(Mason, Moore et al. 1999)
B2AR_human	β_2-adrenergic beta-2AR	C-terminal IC3 loop	266 272 FCLKEHKALKTLGI SR K A	adenylyl cyclase activation; agonist binding affinity / COS-7 or CHO	(Samama, Cotecchia et al. 1993); (Lefkowitz, Cotecchia et al. 1993)
DADR_human	dopamine D1A	carboxyl terminal IC3	264 SFKMSFKRETKVLKT I K 288 *from D1B receptor* APDTSIKKETKVLKT	adenylyl cyclase; cAMP accumulation / HEK293	(Charpentier, Jarvie et al. 1996)
DADR_human	dopamine D1	TMVI	286 FVCCWLPFFIL A	CAMP accumulation / COS-7	(Cho, Taylor et al. 1996)
HH2R_rat	histamine H_2	IC2	115 FMISLDRYCAV N,A	cAMP production / HEK-293	(Alewijnse, Timmerman et al. 2000)

FIG. 1 (4 of 15)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP III					
OPSD_human	opsin rhodopsin	TMII TMIII TMVII	90 FMVLGGFTSTLY D 113 GCNLEGFFAT Q 292 296 MTIPAFFAKSAAIY E G,E,M ^{292}Ala neutral a.a converted to carboxylate and competes with ^{113}Glu for salt bridge with ^{296}Lys	transducin; phosphorylation by rhodopsin kinase / COS	(Rim and Oprian 1995)
OPSD_human	opsin rhodopsin	TMIII	134 VVLAIERYVVV I,Q,S	transducin; radioligand binding / COS	(Acharya and Karnik 1996)
OPSD_human	opsin rhodopsin	TM6 *plus* TM3	257 RMVIIMVIAFL Y,N *plus* G113Q	transducin, GTPγS uptake / COS	(Han, Smith et al. 1998)
OPSD_human	opsin rhodopsin	TMVII IC2	296 PAFFAKSAAIY G X=E,M natural mutants + 10 different a.a. substitutions disrupts critical salt bridge between ^{296}Lys(TMVII) and ^{113}Glu(TMIII) 134 VVLAIERYVVV Q	transducin; radioligand binding / COS	(Govardhan and Oprian 1994); (Cohen, Yang et al. 1993) (Cohen, Yang et al. 1993)

FIG. 1 (5 of 15)

TRFR_mouse	thyrotropin-releasing hormone TRH-R	carboxyl tail	335 FRKLCNCKQK STOP	$^{45}Ca^{2+}$ efflux, $[Ca^{2+}]$ / Xenopus oocytes; IP formation / AtT20, *stably transfected*	(Matus-Leibovitch, Nussenzveig et al. 1995)

FIG. 1 (6 of 15)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP IV					
BRB2_human	bradykinin B_2 B2 bradykinin BK-2	TMIII TMVI	113 AIISM<u>N</u>LYSSI A 256 LLFIIC<u>W</u>LPFQI F	IP production / COS-7	(Marie, Koch et al. 1999)

FIG. 1 (7 of 15)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP V					
AG2R_rat	AT_{1A} Type-1A angiotensis II	TMIII	111 ASVSFNLYASV A disrupts ^{111}Asn(TMIII)-^{292}Tyr(TMVII) interaction	phospholipase C; IP production / COS-7	(Groblewski, Maigret et al. 1997)
AG2R_rat	AT_{1A} Type-1A angiotensis II	C-terminus of TM7 other multiple mutations	305 LFYGFLGKKFK Q	IP production / HEK-293; intrcellular Ca^{2+} mobilization / CHO	(Parnot, Bardin et al. 2000)
FMLR_human	formylmethionylleucylphenylalanine (fMLPR)	IC1	51 LVIWVAGFRMTHTVTTISYLNKAVA LVVWVTAFEAKRTINAIWFLNLAVA (K above conflicts with SWISS-PROT database)	PI production; phospholipase C stimulation / COS-7	(Amatruda, Dragas-Graonic et al. 1995)
IL8B_human	interleukin-8 receptor B CXCR-2 chemokine	IC2	138 ACISVDRYLAIVH V	IP production; Ca^{2+} moblization and actin polymerization / NIH 3T3	(Burger, Burger et al. 1999)
LSHR_human	luteinizing hormone (LH)	IC3	564 MATNKDTKIAKK G	cAMP production / HEK293	(Kudo, Osuga et al. 1996)
LSHR_human	luteinizing hormone (LH)	TMVI	578 ILIFTDFTCMA G	cAMP production / COS-7	(Shenker, Laue et al. 1993)
LSHR_human	luteinizing hormone (LH)	TM6	571 577 KIAKKMAILIFTDFTCM I I	cAMP production / COS-7	(Kosugi, Van Dop et al. 1995)
LSHR_rat	luteinizing hormone / human chorionic gonadotropin (LH/hCG)	TMVI	556 ILIFTDFTCMA G, Y	cAMP production / HEK 293T	(Bradbury, Kawate et al. 1997; Bradbury and Menon 1999)
OPRD_mouse	delta opiod receptor	TM3	128 KVLSIDYYNMF A,K,H	adenylyl cyclase inhibition / COS-7	(Cavalli, Babey et al. 1999)
OXYR_human	oxytocin	IC2	137 LMSLDRCLAIC A	IP production / COS-7	(Fanelli, Barbier et al. 1999)

FIG. 1 (8 of 15)

PAFR_human	platelet-activating factor (PAF)	C-terminus of IC3	231 EVKRRALWMVCTVLAV R	IP production / COS-7	(Parent, Le Gouill et al. 1996)
PAFR_human	platelet-activating factor (PAF)	TMIII	100 CLFFINTYCSV A	arachnidonate release, IP production, adenylyl cylcase inhibition / CHO	(Ishii, Izumi et al. 1997)
PE23_human	prostaglandin E_3, EP3III EP3IV	C-terminal tail	360 FCQEEFWGN FCQMRKRRLREQEEFWGN ↑truncated	inhibition of adenylyl cyclase / CHO-K1	(Jin, Mao et al. 1997)
PE23_mouse	prostaglandin E_3 EP3	carboxyl-terminal tail	336 KILLRKFCQIRDHT (3α) MMNHL (3β) ↑truncated	inhibition of adenylate cyclase / CHO, *stably expressed*	(Hasegawa, Negishi et al. 1996)
THRR_human	thrombin	EC2 loop	259 268 CHDVLNETLLEGYYAYY DLKD KDF I	$^{45}Ca^{2+}$ efflux, PI hydrolysis, reporter gene induction / COS-7	(Nanevicz, Wang et al. 1996)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	EC1 EC2	486 YYNHAIDWQTG F,M 568 YAKVSICLPMD T	inositol phosphate--diacylglycerol cascade / COS-7	(Parma, Van Sande et al. 1995)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	TMIII TMVII	509 ASELSVYTLTV A 672 YPLNSCANPFL Y	adenylyl cyclase activation / COS-7	(Duprez, Parma et al. 1994)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	TMV	597 VAFVIVCCCHV L	cAMP formation / COS-7 cells	(Esapa, Duprez et al. 1999)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	TMVII	677 CANPFLYAIFT V	cAMP formation / CHO cells	(Russo, Wong et al. 1999)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	IC3	613 621 VRNPQYNPGDKDTKIAK deletion	cAMP formation / COS-7	(Wonerow, Schoneberg et al. 1998)

FIG. 1 (9 of 15)

TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	IC3 / TMVI	623 632 KDTKIAKRMAVLIFTDFICM V I	cAMP activation / COS-7	(Paschke, Tonacchera et al. 1994)
V2R_human	vasopressin V2	IC2	136 LAMTLDRHRAI A	cAMP formation / COS-7	(Morin, Cotte et al. 1998)

FIG. 1 (10 of 15)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS B GROUP I					
CALR_human	human calcitonin hCTR-1 hCTR-2	wild type (native) protein		adenylyl cyclase cAMP production / COS-1	(Cohen, Thaw et al. 1997)
CLASS B GROUP II					
PTRR_human	parathyroid hormone PTH / PTH-related peptide	junction of IC1 and TMII junction of IC3 and TMVI	223 TRNYIHMHLFL R,K 410 KLLKSTLVLMP C,others	cAMP accumulation / COS-7	(Schipani, Jensen et al. 1997)
CLASS B GROUP III					
GIPR_human	glucose-dependent insulinotropic peptide (GIP-R)	TMVI	340 VFAPVTEEQAR P	cAMP production / L293	(Tseng and Lin 1997)
GLR_rat	glucagon	junction of IC loop1 and TMII IC end of TMVI	178 TRNYIHGNLFA R 352 RLARSTLTLIP A	cAMP accumulation / COS-7	(Hjorth, Orskov et al. 1998)
VIPR_human	vasoactive intestinal peptide 1 (VIP)	junction of IC loop 1 and TMII junction of IC loop 3 and TMVI	178 RNYIHMHLFI R *requires functional integrity of the N-terminal EC domain* 343 LARSTLLLIP X= K,P	cAMP production / COS-7 or CHO	(Gaudin, Maoret et al. 1998) (Gaudin, Rouyer-Fessard et al. 1998)

FIG. 1 (11 of 15)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS C					
CASR_human	calcium-sensing	N-terminal EC	TLSFVAQNKIDSLNLDEFCNCSEHI *various substitutions, in multiple combinations*	IP / tsA	(Jensen, Spalding et al. 2000)

FIG. 1 (12 of 15)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS D					
O74283 RCB2 C. cinereus	pheromone	TM6	229 PLSAYQIYLGT P	heterologous yeast assay	(Olesnicky, Brown et al. 1999)
STE2_yeast	pheromone α-factor	TM6	258 QSLLVPSIIFI LL	*lacZ* reporter gene	(Konopka, Margarit et al. 1996)
STE2_yeast	pheromone α-factor	double mutations TM5 and TM6	223 MSFVLVVKLILAIR C C 247 251 DSFHILLIMSCQSLL CC CC *double mutations* shaded *double mutations*	*lacZ* reporter gene / yeast	(Dube, DeCostanzo et al. 2000)
STE3_yeast	pheromone a-factor	IC3	194 DVRDILHCTNS Q	β-galactosidase	(Boone, Davis et al. 1993)
STE2_yeast	pheromone α-factor	TM6	253 258 LIMSCQSLLVPSIIFI L LP	β-galactosidase	(Sommers, Martin et al. 2000)

FIG. 1 (13 of 15)

Bibliography

Acharya, S. and S. S. Karnik (1996). "Modulation of GDP release from transducin by the conserved Glu134-Arg135 sequence in rhodopsin." J Biol Chem 271(41): 25406-11.

Alewijnse, A. E., H. Timmerman, et al. (2000). "The Effect of Mutations in the DRY Motif on the Constitutive Activity and Structural Instability of the Histamine H(2) Receptor." Mol Pharmacol 57(5): 890-898.

Allen, L. F., R. J. Lefkowitz, et al. (1991). "G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity." Proc Natl Acad Sci U S A 88(24): 11354-8.

Amatruda, T. T., 3rd, S. Dragas-Graonic, et al. (1995). "Signal transduction by the formyl peptide receptor. Studies using chimeric receptors and site-directed mutagenesis define a novel domain for interaction with G-proteins." J Biol Chem 270(47): 28010-3.

Blüml, K., E. Mutschler, et al. (1994). "Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors." J Biol Chem 269(29): 18870-6.

Boone, C., N. G. Davis, et al. (1993). "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype." Proc Natl Acad Sci U S A 90(21): 9921-5.

Bradbury, F. A., N. Kawate, et al. (1997). "Post-translational processing in the Golgi plays a critical role in the trafficking of the luteinizing hormone/human chorionic gonadotropin receptor to the cell surface." J Biol Chem 272(9): 5921-6.

Bradbury, F. A. and K. M. Menon (1999). "Evidence that constitutively active luteinizing hormone/human chorionic gonadotropin receptors are rapidly internalized." Biochemistry 38(27): 8703-12.

Burger, M., J. A. Burger, et al. (1999). "Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor." J Immunol 163(4): 2017-22.

Burstein, E. S., T. A. Spalding, et al. (1996). "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains." Biochem Pharmacol 51(4): 539-44.

Cavalli, A., A. M. Babey, et al. (1999). "Altered adenylyl cyclase responsiveness subsequent to point mutations of Asp 128 in the third transmembrane domain of the delta-opioid receptor." Neuroscience 93(3): 1025-31.

Charpentier, S., K. R. Jarvie, et al. (1996). "Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties." J Biol Chem 271(45): 28071-6.

Cho, W., L. P. Taylor, et al. (1996). "Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction." Mol Pharmacol 50(5): 1338-45.

Cohen, D. P., C. N. Thaw, et al. (1997). "Human calcitonin receptors exhibit agonist-independent (constitutive) signaling activity." Endocrinology 138(4): 1400-5.

Cohen, G. B., T. Yang, et al. (1993). "Constitutive activation of opsin: influence of charge at position 134 and size at position 296." Biochemistry 32(23): 6111-5.

Dube, P., A. DeCostanzo, et al. (2000). "Interaction between transmembrane domains five and six of the alpha -factor receptor." J Biol Chem 275(34): 26492-9.

Duprez, L., J. Parma, et al. (1994). "Germline mutations in the thyrotropin receptor gene cause non- autoimmune autosomal dominant hyperthyroidism." Nat Genet 7(3): 396-401.

Egan, C. T., K. Herrick-Davis, et al. (1998). "Creation of a constitutively activated state of the 5- hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs." J Pharmacol Exp Ther 286(1): 85-90.

Esapa, C. T., L. Duprez, et al. (1999). "A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis." Thyroid 9(10): 1005-10.

Fanelli, F., P. Barbier, et al. (1999). "Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis." Mol Pharmacol 56(1): 214-25.

Gaudin, P., J. J. Maoret, et al. (1998). "Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors." J Biol Chem 273(9): 4990-6.

Gaudin, P., C. Rouyer-Fessard, et al. (1998). "Constitutive activation of the human VIP1 receptor." Ann N Y Acad Sci 865: 382-5.

FIG. 1 (14 of 15)

Govardhan, C. P. and D. D. Oprian (1994). "Active site-directed inactivation of constitutively active mutants of rhodopsin." J Biol Chem 269(9): 6524-7.

Groblewski, T., B. Maigret, et al. (1997). "Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation." J Biol Chem 272(3): 1822-6.

Han, M., S. O. Smith, et al. (1998). "Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6." Biochemistry 37(22): 8253-61.

Hasegawa, H., M. Negishi, et al. (1996). "Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity." J Biol Chem 271(4): 1857-60.

Herrick-Davis, K., C. Egan, et al. (1997). "Activating mutations of the serotonin 5-HT2C receptor." J Neurochem 69(3): 1138-44.

Hjorth, S. A., C. Orskov, et al. (1998). "Constitutive activity of glucagon receptor mutants." Mol Endocrinol 12(1): 78-86.

Högger, P., M. S. Shockley, et al. (1995). "Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors." J Biol Chem 270(13): 7405-10.

Hwa, J., R. Gaivin, et al. (1997). "Synergism of constitutive activity in alpha 1-adrenergic receptor activation." Biochemistry 36(3): 633-9.

Ishii, I., T. Izumi, et al. (1997). "Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants." J Biol Chem 272(12): 7846-54.

Jensen, A. A., T. A. Spalding, et al. (2000). "Functional importance of the Ala116-Pro136 region in the calcium-sensing receptor. CONSTITUTIVE ACTIVITY AND INVERSE AGONISM IN A FAMILY C G-PROTEIN-COUPLED RECEPTOR [In Process Citation]." J Biol Chem 275(38): 29547-55.

Jin, J., G. F. Mao, et al. (1997). "Constitutive activity of human prostaglandin E receptor EP3 isoforms." British J Pharmacol 121: 317-23.

Kjelsberg, M. A., S. Cotecchia, et al. (1992). "Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation." J Biol Chem 267(3): 1430-3.

Konopka, J. B., S. M. Margarit, et al. (1996). "Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled alpha-factor receptor." Proc Natl Acad Sci U S A 93(13): 6764-9.

Kosugi, S., C. Van Dop, et al. (1995). "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty." Hum Mol Genet 4(2): 183-8.

Kudo, M., Y. Osuga, et al. (1996). "Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop." J Biol Chem 271(37): 22470-8.

Lefkowitz, R. J., S. Cotecchia, et al. (1993). "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins." Trends Pharmacol Sci 14(8): 303-7.

Liu, J., N. Blin, et al. (1996). "Molecular mechanisms involved in muscarinic acetylcholine receptor- mediated G protein activation studied by insertion mutagenesis." J Biol Chem 271(11): 6172-8.

Marie, J., C. Koch, et al. (1999). "Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI." Mol Pharmacol 55(1): 92-101.

Mason, D. A., J. D. Moore, et al. (1999). "A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor." J Biol Chem 274(18): 12670-4.

Matus-Leibovitch, N., D. R. Nussenzveig, et al. (1995). "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenopus oocytes and AtT20 cells." J Biol Chem 270(3): 1041-7.

Morin, D., N. Cotte, et al. (1998). "The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities." FEBS Lett 441(3): 470-5.

Nanevicz, T., L. Wang, et al. (1996). "Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling." J Biol Chem 271(2): 702-6.

Olesnicky, N. S., A. J. Brown, et al. (1999). "A constitutively active G-protein-coupled receptor causes mating self- compatibility in the mushroom Coprinus." Embo J 18(10): 2756-63.

Parent, J. L., C. Le Gouill, et al. (1996). "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor." J Biol Chem 271(14): 7949-55.

FIG. 1 (15 of 15)

Parma, J., J. Van Sande, et al. (1995). "Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades." Mol Endocrinol 9(6): 725-33.

Pamot, C., S. Bardin, et al. (2000). "Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay." Proc Natl Acad Sci U S A 97(13): 7615-20.

Paschke, R., M. Tonacchera, et al. (1994). "Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid." J Clin Endocrinol Metab 79(6): 1785-9.

Pauwels, P. J., A. Gouble, et al. (1999). "Activation of constitutive 5-hydroxytryptamine1B receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its goalpha protein interactions [In Process Citation]." Biochem J 343 Pt 2: 435-42.

Perez, D. M., J. Hwa, et al. (1996). "Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor." Mol Pharmacol 49(1): 112-22.

Ren, Q., H. Kurose, et al. (1993). "Constitutively active mutants of the alpha 2-adrenergic receptor [published erratum appears in J Biol Chem 1994 Jan 14;269(2):1566]." J Biol Chem 268(22): 16483-7.

Rim, J. and D. D. Oprian (1995). "Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin." Biochemistry 34(37): 11938-45.

Robbins, L. S., J. H. Nadeau, et al. (1993). "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function." Cell 72(6): 827-34.

Russo, D., M. G. Wong, et al. (1999). "A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis." Thyroid 9(1): 13-7.

Samama, P., S. Cotecchia, et al. (1993). "A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model." Journal of Biological Chemistry 268(7): 4625-36.

Scheer, A., T. Costa, et al. (2000). "Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation." Mol Pharmacol 57(2): 219-31.

Scheer, A., F. Fanelli, et al. (1997). "The activation process of the alpha1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate." Proc Natl Acad Sci U S A 94(3): 808-13.

Schipani, E., G. S. Jensen, et al. (1997). "Constitutive activation of the cyclic adenosine 3',5'-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia." Mol Endocrinol 11(7): 851-8.

Shenker, A., L. Laue, et al. (1993). "A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty [see comments]." Nature 365(6447): 652-4.

Sommers, C. M., N. P. Martin, et al. (2000). "A limited spectrum of mutations causes constitutive activation of the yeast alpha-factor receptor." Biochemistry 39(23): 6898-909.

Spalding, T. A., E. S. Burstein, et al. (1998). "Identification of a ligand-dependent switch within a muscarinic receptor." J Biol Chem 273(34): 21563-8.

Spalding, T. A., E. S. Burstein, et al. (1997). "Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6." Biochemistry 36(33): 10109-16.

Tseng, C. C. and L. Lin (1997). "A point mutation in the glucose-dependent insulinotropic peptide receptor confers constitutive activity." Biochem Biophys Res Commun 232(1): 96-100.

Wonerow, P., T. Schoneberg, et al. (1998). "Deletions in the third intracellular loop of the thyrotropin receptor. A new mechanism for constitutive activation." J Biol Chem 273(14): 7900-5.

FIG. 2

Light Emission Induced by the WT CCK-BR vs. a Constitutively Active Mutant



FIG. 3

A Point Mutation Confers Constitutive Activity
to the Rat μ Opioid Receptor



FIG. 4

Forskolin Stimulated HEK293 Cells Transfected
With pcDNA1 and a CRE-luc Construct



FIG. 5

The Rat μ Opioid Receptor Signals Through Gαi



FIG. 6


A Point Mutation Confers Constitutive Activity
to the Rat μ Opioid Receptor
Light Units (CPS)
(SRE-luc + Gq5i)
150K
100K
50K
0
N=11
N=11
Wild type
Mutant
pcDNA1
basal / μ opiod
1 μM DAMGO

FIG. 7

Target Residues Within Class I GPCR's



FIG. 8

TMD III Asn (-14 from DRY) is a Target
for Mutation Induced Constitutive Activity



mμ opioid
bradykinin B2
angiotensin II AT1A

FIG. 9

The 'DRY' Motif is a Target for Mutation
Induced Constitutive Activity



oxytosin
vasopressin-V2
cholecystokinin-A
melanocortin-4
α_{1B} adrenergic

FIG. 10


A Point Mutation Enhances MC-4 Receptor Constitutive Activity
Light units (SMS-luc Reporter)
400K
300K
200K
100K
0
pcDNA1
MC-4 WT
MC-4 D146M
basal
a-MSH

FIG. 11

The -13 Position is a Target for Mutation
Induced Constitutive Activity



α_{1A} adrenergic
α_{2C} adrenergic
β_2 adrenergic
serotonin 2A
cholecystokinin-B
platelet activating factor
thyroid stimulating hormone

FIG. 12

```
ork    1   -----------MESPI    FRGEPGPTCAPSACLPPNSSAWFPGWAEP    SNGSAGSEDAQ
orkr   1   -----------MESPIQIFRGEPGPTCAPSACLLPNSSSWFPNWAES..DSNGSVGSEDQQ
orm    1   MDSSAAPTNASNCTDALAYSSCSPAPSPGSWV..NLSHLDGNLSDPCGPNRTDLGGRDSL
ormr   1   MDSSTGPGNTSDCSDPLAQASCSPA..PGSWL..NLSHVDGNQSDPCGLNRTGLGGNDSL
ord    1   ---------------------MEPAPSAGAEL..Q.PPLFANASDAYPSACPSACANASG
AT1a   1   ---------------------------------------------MALNSSAEDGIKRIQ
BK-2   1   ---------------MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNG.TFAQ

ork   49   LEPAHISPAI..PVIITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADA
orkr  49   LEPAHISPAI..PVIITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADA
orm   59   CPPTGS.PSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADA
ormr  57   CPQTGS.PSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADA
ord   37   PPGARSASSLALAIAITALYSAVCAVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADA
AT1a  16   DDCPKAGRHSYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADL
BK-2  45   SKCPQVEWLGWLNTIQPPFLWVLFVLATLENIFVLSVFCLHKSSCTVAEIYLGNLAAADL

ork  107   LVTTTMPFQSTVYLMN.SWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVK
orkr 107   LVTTTMPFQSAVYLMN.SWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVK
orm  118   LATSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVK
ormr 116   LATSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVK
ord   97   LATSTLPFQSAKYLME.TWPFGELLCKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVK
AT1a  76   CFLLTLPLWAVYTAMEYRWPFGNHLCKIASASVTFNLYASVFLLTCLSIDRYLAIVHPMK
BK-2 105   LLACGLPFWAITISNNFDWLFGETLCRVVNAIISMNLYSSICFLMLVSIDRYLALVKTMS
                                                    ↑                    *
                                              -14 from DRY

ork  166   ALDFRTPLKAKIINICIWLLSSSVGISAIVLGGTKVR..EDVDVIECSLQFPDDDYSWWD
orkr 166   ALDFRTPLKAKIINICIWLLASSVGISAIVLGGTKVR..EDVDVIECSLQFPDDEYSWWD
orm  177   ALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYR..Q..GSIDCTLTFSHPTW.YWE
ormr 175   ALDFRTPRNAKIVNVCNWILSSAIGLPVMFMATTKYR..Q..GSIDCTLTFSHPTW.YWE
ord  156   ALDFRTPAKAKLINICIWVLASGVGVPIMVMAVTRPR..D..GAVVCMLQFPSPSW.YWD
AT1a 136   SRLRRTMLVAKVTCIIIWLMAGLASLPAVIHRNV..YFIENTNITVCAFHYESRN.STLP
BK-2 165   MGRMRGVRWAKLYSLVIWGCTLLLSSPMLVFRTMKEYSDEGHNVTACVISYPS...LIWE

ork  224   LFMKICVFIFAFVIPVLIIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVF
orkr 224   LFMKICVFVFAFVIPVLIIIVCYTLMILRLKSVRLLSGSREKDRNLRRITKLVLVVVAVF
orm  232   NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
ormr 230   NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
ord  211   TVTKICVFLFAFVVPILIITVCYGLMLLRLRSVRLLSGSKEKDRSLRRITRMVLVVVGAF
AT1a 193   IGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDD...IFRIIMAIVLFF
BK-2 222   VFTNMLLNVVGFLLP.LSVITFCTMQIMQVLRNNEMQKFKEIQTE.RRATVLVLVVLLLF

ork  284   VVCWTPIHIFILVEALGS.T.....SHSTAALSSYYFCIALGYTNSSLNPILYAFLDENF
orkr 284   IICWTPIHIFILVEALGS.T.....SHSTAVLSSYYFCIALGYTNSSLNPVLYAFLDENF
orm  292   IVCWTPIHIYVIIKALITIP.......ETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
ormr 290   IVCWTPIHIYVIIKALITIP.......ETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
ord  271   VVCWAPIHIFVIVWTLVDID.....RRDPLVVAALHLCIALGYANSSLNPVLYAFLDENF
AT1a 250   FFSWVPHQIFTFLDVLIQLGVIHDCKISDIVDTAMPITICIAYFNNCLNPLFYGFLGKKF
BK-2 280   IICWLPFQISTFLDTLHRLGILSSCQDERIIDVITQIASFMAYSNSCLNPLVYVIVGKRF

                                                             SEQ ID NO:
ork  338   KRCFRDFCFPIKMRMERQSTSRVR.NTVQD.PAYLRDIDGMNKPV------------ 76
orkr 338   KRCFRDFCFPIKMRMERQSTNRVR.NTVQD.PASMRDVGGMNKPV------------ 77
orm  346   KRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP 78
ormr 344   KRCFREFCIPTSSTIEQQNSTRVRQNTREHPSTANTVDRTNHQLENLEAETAPLP 79
ord  326   KRCFRQLCRKPCGRPDPSSFSRAREATARERVTACTPSDGPGGGAAA---------- 80
AT1a 310   KKYFLQLLKYIPPKAKSHS...SLSTKM..STLSYRPSDNMSSSAKKPASCFEVE- 81
BK-2 340   RKKSWEVYQGVCQKGGCRSEPIQMENSM..GTL..RTSISVERQIHKLQDWAGSRQ 82
```

FIG. 13

```
mORmouse    1 MDSSAGPGNISDCSDPLA.PASCSPA..PGSWLNLSHVDGNQSDPCGPNRTGLGGSHSLC
mORrat      1 MDSSTGPGNTSDCSDPLA.QASCSPA..PGSWLNLSHVDGNQSDPCGLNRTGLGGNDSLC
mORbovin    1 MDSGAVPTNASNCTDPFTHPSSCSPAPSPSSWVNFSHLEGNLSDPCGPNRTELGGSDRLC
mORhuman    1 MDSSAAPTNASNCTDALAY.SSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLC
mORpig      1 MDSSADPRNASNCTDPFSPSSMCSPVPSPSSWVNFSHLEGNLSDPCIRNRTELGGSDSLC
mORws       1 MENS...GNISDFLYPIS.....NPVMS.....NSSVLCRNFSNSTSFLNMNGSSRDSTD
AT1a        1 -----------------------------------------MALNSSAEDGIKRIQDDC
BK-2        1 ------------MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNG.TFACSKC

mORmouse   58 PQTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORrat     58 PQTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORbovin   61 PSAGSPSMITAIIIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORhuman   60 PPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORpig     61 PPTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORws      48 EQDKTLP.VIIAIIITTLYSIVCVVGLVGNVLVMYVIIRYTKMKTATNIYIFNLALADALA
AT1a       19 PKAGRHSYIFVM.IPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADLCF
BK-2       48 PQVEWLGWLNTI.QPPFLWVLFVLATLENIFVLSVFCLHKSSCTVAEIYLGNLAAADLIL

mORmouse  118 TSTLPFQSVNYLMG.TWPFGNILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORrat    118 TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORbovin  121 TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORhuman  120 TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORpig    121 TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLTTMSTDRYIAVCHPVKAL
mORws     107 TSTLPFQSVNYLMG.TWPFGDVVCKIVMSIDYYNMFTSIFTLTTMSIDRYIAVCHPVKAL
AT1a       78 LLTLPLWAVYTAMEYRWPFGNHLCKIASASVTFNLYASVFLLTCLSIDRYLAIVHPMKSR
BK-2      107 ACGLPFWAITISNNFDWLFGETLCRVVNAIISMNLYSSICFLMLVSIDRYLALVKTMSMG
                                                 *

mORmouse  177 DFRTPRNAKIVNVCNWILSSAIGLPVMFMATTKYRQ.......GSIDCTLTFSHPTWYWE
mORrat    177 DFRTPRNAKIVNVCNWILSSAIGLPVMFMATTKYRQ.......GSIDCTLTFSHPTWYWE
mORbovin  180 DLRTPRNAKIINICNWILSSAIGLPVMFMATTKYRQ.......GSIDCTLTFSHPTWYWE
mORhuman  179 DFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQ.......GSIDCTLTFSHPTWYWE
mORpig    180 DFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRN.......GSIDCALTFSHPTWYWE
mORws     166 DFRTPRNAKIVNVCNWILSSAIGLPVMVMASTTIENQNSPLQVSNFDCTLLFPHPPWYWE
AT1a      138 LRRTMLVAKVTCIIIWLMAGLASLPAVIHRNV.....YFIENTNITVCAFHYESRNSTLP
BK-2      167 RMRGVRWAKLYSLVIWGCTLLLSSPMLVFRTMK...EYSDEGHNVTACVISYPS..LIWE

mORmouse  230 NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORrat    230 NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORbovin  233 NLLKICVFIFAFIMPILIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORhuman  232 NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORpig    233 NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORws     226 TLLKICVFILAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
AT1a      193 IGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDD...IFRIIMAIVLFF
BK-2      222 VFTNMLLNVVGFLLP.LSVITFCTMQIMQVLRNNEMQKFKEIQTE.RRATVLVLVVLLLF

mORmouse  290 IVCWTPIHIYVIIKALITI......PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORrat    290 IVCWTPIHIYVIIKALITI......PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORbovin  293 IVCWTPIHIYVIIKALITI......PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORhuman  292 IVCWTPIHIYVIIKALVTI......PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORpig    293 IVCWTPIHIYVIIKALITI......PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORws     286 IICWTPIHIFVIIKALVTI......PNSLFQTVIWHFCIALGYTNSCLNPVLYAFLDENF
AT1a      250 .FFSWVPHQIFTFLDVLIQLGVIHDCKISDIVDTAMPITICIAYFNNCLNPLFYGFLGKKF
BK-2      280 IICWLPFQISTFLDTLHRLGILSSCQDERIIDVITQIASFMAYSNSCLNPLVYVIVGKRF

                                                                SEQ ID NO:
mORmouse  344 KRCFREFC..IPTSSTIEQQNSARIRQNTREHPSTANTVDRTNHQLENLEAETAPLP 83
mORrat    344 KRCFREFC..IPTSSTIEQQNSTRVRQNTREHPSTANTVDRTNHQLENLEAETAPLP 79
mORbovin  347 KRCFREFC..IPTSSTIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETTPLP 84
mORhuman  346 KRCFREFC..IPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP 85
mORpig    347 KRCFREFC..IPTSSTIEQQNSARIRQNTREHPSTANTVDRTNHQLENLEAETAPLP 86
mORws     340 KRCFREFC..VPSPSVLDLQNSTRNSNPQQEGQSSGHKVDRNNRQV----------- 87
AT1a      310 KKYFLQLLKYIPPKAKSHS...SLSTKMSTLSYRPSDNMSSSAKKPASCFEVE---- 81
BK-2      340 RKKSWEVYQGVCQKGGCRSEPIQMENSMGTL..RTSISVERQIHKLQDWAGSRQ--- 82
```